UNSPSC 51162606: Benproperine pamoate

This classification denotes an antitussive agent with the molecular formula C23H16O6.2C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 370C8CB2K3. Most nations, for tariff and trade purposes, schedule benproperine pamoate under HS 29333999. As of Q4 2014, BENPROPERINE PAMOATE remains US FDA's Preferred Term for this commodity. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51162606 Benproperine pamoate is a Commodity code that nominally designates a specific pharmaceutical active ingredient, but recent state and local solicitations tagged with this code actually procure naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products for public health and community health initiatives. State and local governments buy these items through both direct county procurements and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. Issuing bodies include county health departments and state-level cooperative purchasing alliances that serve participating state and local government facilities.

Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, represent the recent activity on this code. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. The MMCAP procurement requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, with pricing evaluated on a 75 percent weight and administrative and compliance criteria on the remainder.